Company intelligence / Profile preview

Committee of Technology

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Committee of Technology (COT) is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to the development of mRNA-based therapeutics and vaccines. The company leverages its proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery platforms to create a diverse pipeline targeting infectious diseases and oncology. COT's most advanced candidate is an mRNA vaccine for COVID-19, which has undergone clinical evaluation in China. Additionally, the company is expanding its research into personalized cancer vaccines and protein replacement therapies to address various high-need medical conditions.

Therapeutic areas: Infectious DiseasesOncology
Modalities: mRNA-based drugsVaccineLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Committee of Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Committee of Technology.

Explore the full profile